Education
About Us
Working with TipRanks
Follow Us
Epigenomics (GB:0QXH)
LSE:0QXH
0QXH Stock Chart & Stats
€0.88
€0.00(0.00%)
At close: 4:00 PM EST
€0.88
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.88 - €1.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€762.95K
Enterprise Value€11.18M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding876,949
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
0QXH FAQ
What was Epigenomics’s price range in the past 12 months?
Epigenomics lowest share price was €0.88 and its highest was €1.50 in the past 12 months.
What is Epigenomics’s market cap?
Epigenomics’s market cap is €762.95K.
When is Epigenomics’s upcoming earnings report date?
Epigenomics’s upcoming earnings report date is Aug 12, 2026 which is in 233 days.
How were Epigenomics’s earnings last quarter?
Epigenomics released its earnings results on Aug 06, 2025. The company reported -€0.233 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.233.
Is Epigenomics overvalued?
According to Wall Street analysts Epigenomics’s price is currently Overvalued.
Does Epigenomics pay dividends?
Epigenomics does not currently pay dividends.
What is Epigenomics’s EPS estimate?
Epigenomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigenomics have?
Epigenomics has 876,949 shares outstanding.
What happened to Epigenomics’s price movement after its last earnings report?
Epigenomics reported an EPS of -€0.233 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Epigenomics?
Currently, no hedge funds are holding shares in GB:0QXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Epigenomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-78.37%
Trailing 12-Months
Company Description
Epigenomics
Epigenomics AG is a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, North America, Asia, and the Rest of the world.
Technical Analysis
B.R.A.I.N. Biotechnology Research and Information Network
―
Heidelberg Pharma AG
―
Bio-Gate AG
―
Vitruvia Medical AG
―
―